{"schema_version":"1.0","type":"article","title":"GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法","url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.md","lang":"zh-Hant","date":"2026-06-19","publish_at":"2026-06-19T08:00:00+08:00","updated_at":"2026-06-19","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資"],"summary":"2026 年 6 月 9 日，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元，較 Nuvalent 前一交易日收盤價溢價約 40%。這是 GSK 近年最大型的腫瘤併購之一，也讓它瞬間補上肺癌精準治療版圖中最缺的一塊。","key_points":[],"facts":[],"sections":["01｜Nuvalent 的選擇：不搶新靶點，而是把老靶點做到更深","02｜Zidesamtinib：ROS1 治療裡，真正難的是 G2032R 與腦轉移","03｜Neladalkib：ALK 藥物已經很多，但複合耐藥仍然是下一道牆","04｜NVL-330：HER2 肺癌仍缺口服小分子解法","05｜GSK 為什麼願意花 106 億美元？","06｜這筆交易的本質：肺癌靶向治療從「有藥可用」走向「把藥做到更好」","07｜風險在哪裡？上市不是終點，真正考試在一線","08｜台灣可以看「工程化創新」能力","結語｜GSK 106 億美元買下的，是肺癌靶向治療下一階段的入場券"],"references":[{"title":"[1] GSK","source":"Investor relations and company announcements:","date":"","url":"https://www.gsk.com/en-gb/investors/"},{"title":"[2] Nuvalent","source":"Investor relations and company news:","date":"","url":"https://investors.nuvalent.com/"},{"title":"[3] Nuvalent","source":"Pipeline overview:","date":"","url":"https://www.nuvalent.com/pipeline/"},{"title":"[4] Reuters","source":"Health and pharmaceutical M&A coverage:","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/"}],"images":[{"alt":"Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 1）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-01.png"},{"alt":"Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 2）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-02.png"},{"alt":"Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 3）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-03.png"},{"alt":"Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 4）","url":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-19）。GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法。https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}